,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2014-01-22 08:10:00,St. Jude Medical Inc. ( STJ ) posted a 7.6% rise in adjusted net earnings per share to 99 cents for the fourth quarter of 2013 from 92 cents a year-ago and beat the Zacks Consensus Estimate by 3 cents.,0.9574847221374512,0.025574201717972755,0.016940990462899208,positive,0.931910514831543
1,2014-01-22 08:10:00,"Reported earnings were $123 million or 42 cents per share in the quarter, compared with $120 million or 39 cents per share in the comparable quarter of 2012.",0.386488676071167,0.5754207372665405,0.03809059038758278,negative,-0.18893206119537354
2,2014-01-22 08:10:00,"For full-year 2013, adjusted net earnings rose 8.0% to $3.76 per share from $3.48 per share in the prior year.",0.9582576155662537,0.02408011630177498,0.017662230879068375,positive,0.9341775178909302
3,2014-01-22 08:10:00,Reported net earnings were $723 million or $2.49 per share in the year compared with $2.39 in 2012.,0.2591570317745209,0.6860136389732361,0.054829325526952744,negative,-0.4268566071987152
4,2014-01-22 08:10:00,"Revenues for the year grew 3.6% to $1,422 million for the quarter, exceeding the Zacks Consensus Estimate of $1,381 million.",0.957306981086731,0.022526727989315987,0.02016635611653328,positive,0.9347802400588989
5,2014-01-22 08:10:00,Unfavorable foreign currency translation reduced revenues by roughly $27 million.,0.01658288575708866,0.9734859466552734,0.009931212291121483,negative,-0.9569030404090881
6,2014-01-22 08:10:00,"At constant currency, net revenues increased 6% over the prior-year quarter.",0.9588247537612915,0.019520152360200882,0.021655116230249405,positive,0.9393045902252197
7,2014-01-22 08:10:00,Revenues from the U.S. rose 4.7% to $641 million while international revenues increased 2.4% to $641 million.,0.9565310478210449,0.02052302286028862,0.02294597588479519,positive,0.9360080361366272
8,2014-01-22 08:10:00,"For the full-year, net revenues declined marginally to $5,501 million from $5,503 million in 2012 as unfavorable foreign currency translation reduced revenues by roughly $101 million.",0.016194423660635948,0.9746604561805725,0.009145091287791729,negative,-0.9584660530090332
9,2014-01-22 08:10:00,"With this, net revenues missed the Zacks Consensus Estimate of $5,460 million.",0.023255780339241028,0.9649025201797485,0.01184161752462387,negative,-0.9416467547416687
10,2014-01-22 08:10:00,"At constant-currency, net revenues grew 2% over the prior year.",0.9584664106369019,0.021065276116132736,0.020468328148126602,positive,0.9374011158943176
11,2014-01-22 08:10:00,"In the Cardiac Rhythm Management (CRM) division, revenues went up 3% to $705 million, while it increased 5% excluding the impact of foreign currency.",0.9592986106872559,0.020203331485390663,0.02049807645380497,positive,0.9390952587127686
12,2014-01-22 08:10:00,"However, CRM revenues slipped 2% to $2,783 million in 2013, and fell 1% at constant currency.",0.016522405669093132,0.9746992588043213,0.008778314106166363,negative,-0.958176851272583
13,2014-01-22 08:10:00,"Of the total revenues in the CRM division, implantable cardiac defibrillator (ICD) revenues escalated 5% (both on a reported and constant-currency basis) to $442 million.",0.8919984698295593,0.05447380989789963,0.05352774262428284,positive,0.8375246524810791
14,2014-01-22 08:10:00,"For the full-year 2013, ICD product revenues were flat at $1,741 million, compared with 2012.",0.016759423539042473,0.9652627110481262,0.017977818846702576,negative,-0.948503315448761
15,2014-01-22 08:10:00,"However, on a constant-currency basis, ICD revenues inched up a meager 1% over the prior year.",0.8582926988601685,0.11742357909679413,0.024283697828650475,positive,0.7408691048622131
16,2014-01-22 08:10:00,"In the CRM division, pacemaker revenues inched up 1% to $263 million.",0.9571971893310547,0.02105911448597908,0.021743692457675934,positive,0.9361380934715271
17,2014-01-22 08:10:00,"At constant-currency, pacemaker product revenues rose 4% in the quarter.",0.9570363163948059,0.017981698736548424,0.02498200349509716,positive,0.9390546083450317
18,2014-01-22 08:10:00,"However, for 2013, pacemaker revenues went down 6% to $1,042 million, and declined 4% at constant-currency.",0.016143040731549263,0.972851574420929,0.011005322448909283,negative,-0.956708550453186
19,2014-01-22 08:10:00,"In the Atrial Fibrillation (AF) division, revenues scaled up 5% to $252 million, while at constant currency it increased 8% over the fourth quarter of 2012.",0.9572235941886902,0.01758532039821148,0.025190984830260277,positive,0.9396382570266724
20,2014-01-22 08:10:00,"For full-year 2013, AF product revenues escalated 7% to $957 million, and rose 9% at constant-currency.",0.9547250866889954,0.021949023008346558,0.02332594059407711,positive,0.9327760934829712
21,2014-01-22 08:10:00,"In the Cardiovascular division, revenues grew 4% to $350 million in the quarter and rose 7% at constant-currency.",0.9525237679481506,0.01622675731778145,0.031249506399035454,positive,0.9362969994544983
22,2014-01-22 08:10:00,"For 2013, cardiovascular revenues rose marginally by 1% to $1,335 million from the prior year.",0.9405508041381836,0.04043053090572357,0.019018618389964104,positive,0.9001202583312988
23,2014-01-22 08:10:00,"At constant-currency, cardiovascular revenues increased 3% in the year.",0.9555571675300598,0.01671135053038597,0.027731463313102722,positive,0.9388458132743835
24,2014-01-22 08:10:00,"Of the total revenues in cardiovascular division, vascular product revenues edged up 2% to $183 million at constant currency.",0.9571044445037842,0.02071438543498516,0.02218109369277954,positive,0.9363900423049927
25,2014-01-22 08:10:00,"For 2013, vascular product revenues rose 2% to $704 million at constant currency.",0.9576514363288879,0.017169326543807983,0.025179199874401093,positive,0.9404821395874023
26,2014-01-22 08:10:00,"Meanwhile, structural heart product revenues grew 12% to $167 million at constant currency.",0.9555005431175232,0.015910694375634193,0.028588792309165,positive,0.9395898580551147
27,2014-01-22 08:10:00,"For 2013, structural heart product revenues rose 3% to $631 million, and went up 5% at constant currency.",0.9546329379081726,0.018440673127770424,0.026926415041089058,positive,0.9361922740936279
28,2014-01-22 08:10:00,"In the Neuromodulation division, revenues went up 2% to $115 million in the fourth quarter, both on a reported and constant-currency basis.",0.9569780230522156,0.01946788839995861,0.023554086685180664,positive,0.9375101327896118
29,2014-01-22 08:10:00,Total neuromodulation product revenues for 2013 edged up 1% to $426 million over 2012 level.,0.9558528661727905,0.022975927218794823,0.021171148866415024,positive,0.9328769445419312
30,2014-01-22 08:10:00,"St. Jude Medical had cash and cash equivalents of $1,373 million as of Dec 28, 2013, up 15.0% from $1,194 million as of Dec 29, 2012.",0.955764889717102,0.021499741822481155,0.02273532934486866,positive,0.93426513671875
31,2014-01-22 08:10:00,"Total debt rose 16.2% to $3,580 million as of Dec 28, 2013 compared with $3,080 million as of Dec 29, 2012.",0.9518093466758728,0.02253042533993721,0.025660188868641853,positive,0.9292789101600647
32,2014-01-22 08:10:00,"Consequently, debt-to-capitalization increased to 44.8% from 42.9% as of Dec 29, 2012.",0.9581471681594849,0.022373825311660767,0.019478965550661087,positive,0.9357733726501465
33,2014-01-22 08:10:00,"For the first quarter of 2014, STJ expects revenues in the range of $1,280 million to $1,360 million while the company anticipates adjusted net earnings per share to lie between 94 cents and 96 cents for the quarter.",0.10963861644268036,0.019421741366386414,0.8709396123886108,neutral,0.09021687507629395
34,2014-01-22 08:10:00,"The current Zacks Consensus Estimates for earnings per share and revenues for the quarter are pegged at 96 cents and $1,372 million.",0.025841305032372475,0.025836605578660965,0.9483221173286438,neutral,4.699453711509705e-06
35,2014-01-22 08:10:00,"For full year 2014, St. Jude Medical anticipates revenues in the range of $5,600 million to $5,750 million and adjusted net earnings per share between $3.94 and $3.99.",0.062290292233228683,0.01345638744533062,0.9242532849311829,neutral,0.04883390665054321
36,2014-01-22 08:10:00,"The current Zacks Consensus Estimates for earnings per share and revenues for the year are pegged at $3.98 and $5,644 million.",0.026946978643536568,0.030913500115275383,0.9421395659446716,neutral,-0.003966521471738815
37,2014-01-22 08:10:00,"We are impressed with STJ's fourth quarter results, which topped estimates at both fronts.",0.941201388835907,0.01697472110390663,0.04182383045554161,positive,0.9242266416549683
38,2014-01-22 08:10:00,"Moreover, the company's clear-cut guidance is encouraging.",0.9312635660171509,0.013963744975626469,0.054772764444351196,positive,0.9172998070716858
39,2014-01-22 08:10:00,"Currently, St. Jude carries a Zacks Rank #3 (Hold).",0.03662055358290672,0.021883057430386543,0.9414964318275452,neutral,0.01473749615252018
40,2014-01-22 08:10:00,"Some better-ranked stocks in the medical products industry include Cardiovascular Systems Inc. ( CSII ), Covidien plc ( COV ), and NuVasive, Inc. ( NUVA ).",0.7231139540672302,0.024836061522364616,0.25204992294311523,positive,0.6982778906822205
41,2014-01-22 08:10:00,All of them carry a Zacks Rank #1 (Strong Buy).,0.4791254997253418,0.022617850452661514,0.4982565939426422,neutral,0.4565076529979706
42,2014-01-22 08:10:00,To read this article on Zacks.com click here.,0.017961200326681137,0.01924508437514305,0.9627937078475952,neutral,-0.001283884048461914
43,2014-01-22 08:10:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204561054706573,0.01563790813088417,0.9741575717926025,neutral,-0.005433347076177597
